The DOI matches its Crossref record; 171 of the 171 references it cites were found in a registry or an index.
A brief history of the development of antidepressant drugs: From monoamines to glutamate.
Open accessAbstract
Major depressive disorder (MDD) is a chronic, recurring, and debilitating mental illness that is the most common mood disorder in the United States. It has been almost 50 years since the monoamine hypothesis of depression was articulated, and just over 50 years since the first pharmacological treatment for MDD was discovered. Several monoamine-based pharmacological drug classes have been developed and approved for the treatment of MDD; however, remission rates are low (often less than 60%) and there is a delayed onset before remission of depressive symptoms is achieved. As a result of a "proof-of-concept" study in 2000 with the noncompetitive NMDA antagonist ketamine, a number of studies have examined the glutamatergic systems as viable targets for the treatment of MDD. This review will provide a brief history on the development of clinically available antidepressant drugs, and then review the possible role of glutamatergic systems in the pathophysiology of MDD. Specifically, the glutamatergic review will focus on the N-methyl-D-aspartate (NMDA) receptor and the efficacy of drugs that target the NMDA receptor for the treatment of MDD. The noncompetitive NMDA receptor antagonist ketamine, which has consistently produced rapid and sustained antidepressant effects in MDD patients in a number of clinical studies, has shown the most promise as a novel glutamatergic-based treatment for MDD. However, compounds that target other glutamatergic mechanisms, such as GLYX-13 (a glycine-site partial agonist at NMDA receptors) appear promising in early clinical trials. Thus, the clinical findings to date are encouraging and support the continued search for and the development of novel compounds that target glutamatergic mechanisms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Koretz, D., Merikangas, K. R., Rush, A. J., Walters, E. E., & Wang, P. S. (2003) · JAMA · doi:10.1001/jama.289.23.3095 · Cited by 7,988
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
THE CATECHOLAMINE HYPOTHESIS OF AFFECTIVE DISORDERS: A REVIEW OF SUPPORTING EVIDENCE
SCHILDKRAUT, J. J. (1965) · American Journal of Psychiatry · doi:10.1176/ajp.122.5.509 · Cited by 3,492
Kessler, R. C., Petukhova, M., Sampson, N. A., Zaslavsky, A. M., & Wittchen, H. (2012) · International Journal of Methods in Psychiatric Research · doi:10.1002/mpr.1359 · Cited by 2,947 · cited 3×
“Females are two-to-three times more likely to be diagnosed with MDD as compared to their male counterparts regardless of age group (Kessler et al., 2012).”
BackgroundmTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881
The metabotropic glutamate receptors: Structure and functions
Pin, J.-P., & Duvoisin, R. (1995) · Neuropharmacology · doi:10.1016/0028-3908(94)00129-g · Cited by 2,266
NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926
Diagnosis and definition of treatment-resistant depression
Fava, M. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00231-2 · Cited by 1,380
The Economic Burden of Depression in the United States: How Did It Change Between 1990 and 2000?
Greenberg, P. E., Kessler, R. C., Birnbaum, H. G., Leong, S. A., Lowe, S. W., Berglund, P. A., & Corey-Lisle, P. K. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n1211 · Cited by 1,280
Murrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Green, C. E., Perez, A. M., Iqbal, S., Pillemer, S., Foulkes, A., Shah, A., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13030392 · Cited by 1,205
Norepinephrine in Depressive Reactions: A Review
BUNNEY, W. E. (1965) · Archives of General Psychiatry · doi:10.1001/archpsyc.1965.01730060001001 · Cited by 1,153
Bymaster, F. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00346-9 · Cited by 1,123
Diazgranados, N., Ibrahim, L., Brutsche, N. E., Newberg, A., Kronstein, P., Khalife, S., Kammerer, W. A., Quezado, Z., Luckenbaugh, D. A., Salvadore, G., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.90 · Cited by 963
Rothman, R. B., Baumann, M. H., Dersch, C. M., Romero, D. V., Rice, K. C., Carroll, F. I., & Partilla, J. S. (2001) · Synapse · doi:10.1002/1098-2396(20010101)39:1<32::aid-syn5>3.0.co;2-3 · Cited by 938
Hasler, G., van der Veen, J. W., Tumonis, T., Meyers, N., Shen, J., & Drevets, W. C. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.2.193 · Cited by 846
DEFINITION AND EPIDEMIOLOGY OF TREATMENT-RESISTANT DEPRESSION
Fava, M., & Davidson, K. G. (1996) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(05)70283-5 · Cited by 797
Subtype-Specific Alterations of γ-Aminobutyric Acid and Glutamatein Patients With Major Depression
Sanacora, G., Gueorguieva, R., Epperson, C. N., Wu, Y.-T., Appel, M., Rothman, D. L., Krystal, J. H., & Mason, G. F. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.7.705 · Cited by 796
Ionotropic and metabotropic glutamate receptor structure and pharmacology
Kew, J. N. C., & Kemp, J. A. (2005) · Psychopharmacology · doi:10.1007/s00213-005-2200-z · Cited by 788
Murrough, J. W., Perez, A. M., Pillemer, S., Stern, J., Parides, M. K., aan het Rot, M., Collins, K. A., Mathew, S. J., Charney, D. S., & Iosifescu, D. V. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.06.022 · Cited by 786
Bymaster, F. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00298-6 · Cited by 717
Safety and Efficacy of Repeated-Dose Intravenous Ketamine for Treatment-Resistant Depression
aan het Rot, M., Collins, K. A., Murrough, J. W., Perez, A. M., Reich, D. L., Charney, D. S., & Mathew, S. J. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.08.038 · Cited by 690
(2000) · PubMed · Cited by 685
Neurotransmitter Receptor and Transporter Binding Profile of Antidepressants and Their Metabolites
Owens, M. J., Morgan, W. N., Plott, S. J., & Nemeroff, C. B. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37161-7 · Cited by 676
Choudary, P. V., Molnar, M., Evans, S. J., Tomita, H., Li, J. Z., Vawter, M. P., Myers, R. M., Bunney, W. E., Akil, H., Watson, S. J., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507901102 · Cited by 652
Wong, D. T., Bymaster, F. P., & Engleman, E. A. (1995) · Life Sciences · doi:10.1016/0024-3205(95)00209-o · Cited by 647
THE TREATMENT OF DEPRESSIVE STATES WITH G 22355 (IMIPRAMINE HYDROCHLORIDE)
KUHN, R. (1958) · American Journal of Psychiatry · doi:10.1176/ajp.115.5.459 · Cited by 615
Increased Levels of Glutamate in Brains from Patients with Mood Disorders
Hashimoto, K., Sawa, A., & Iyo, M. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.03.017 · Cited by 609
Bang-Andersen, B., Ruhland, T., Jørgensen, M., Smith, G., Frederiksen, K., Jensen, K. G., Zhong, H., Nielsen, S. M., Hogg, S., Mørk, A., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101459g · Cited by 606
Price, R. B., Nock, M. K., Charney, D. S., & Mathew, S. J. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.04.029 · Cited by 600
Auer, D. P., Pütz, B., Kraft, E., Lipinski, B., Schill, J., & Holsboer, F. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00159-6 · Cited by 564
Prevalence of Sexual Dysfunction Among Newer Antidepressants
Clayton, A. H., Pradko, J. F., Croft, H. A., Montano, C. B., Leadbetter, R. A., Bolden-Watson, C., Bass, K. I., Donahue, R. M. J., Jamerson, B. D., & Metz, A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0414 · Cited by 542
Domino, E. F., & Warner, D. S. (2010) · Anesthesiology · doi:10.1097/aln.0b013e3181ed09a2 · Cited by 520
Fava, M., Rush, A. J., Trivedi, M. H., Nierenberg, A. A., Thase, M. E., Sackeim, H. A., Quitkin, F. M., Wisniewski, S., Lavori, P. W., Rosenbaum, J. F., et al. (2003) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(02)00107-7 · Cited by 519
Preskorn, S. H., Baker, B., Kolluri, S., Menniti, F. S., Krams, M., & Landen, J. W. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31818a6cea · Cited by 518
Uptake of Catecholamines by a Particulate Fraction of the Adrenal Medulla
Kirshner, N. (1962) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)63439-3 · Cited by 506
Stahl, S. M., Pradko, J., Haight, B. R., Modell, J. G., Rockett, C. B., & Learned-Coughlin, S. (2004) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v06n0403 · Cited by 495
Stahl, S. M. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n0103 · Cited by 489
Wong, D. T., Horng, J. S., Bymaster, F. P., Hauser, K. L., & Molloy, B. B. (1974) · Life Sciences · doi:10.1016/0024-3205(74)90345-2 · Cited by 481
A Randomized Controlled Trial of Intranasal Ketamine in Major Depressive Disorder
Lapidus, K. A. B., Levitch, C. F., Perez, A. M., Brallier, J. W., Parides, M. K., Soleimani, L., Feder, A., Iosifescu, D. V., Charney, D. S., & Murrough, J. W. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.03.026 · Cited by 480
Kapur, S., & Seeman, P. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001093 · Cited by 459
Schulberg, H. C., Katon, W., Simon, G. E., & Rush, A. J. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.12.1121 · Cited by 459
Stahl, S. M., Grady, M. M., Moret, C., & Briley, M. (2005) · CNS Spectrums · doi:10.1017/s1092852900019726 · Cited by 458
McIntyre, R. S., Lophaven, S., & Olsen, C. K. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145714000546 · Cited by 433
5-Hydroxytryptamine in the Hind-Brain of Depressive Suicides
Shaw, D. M., Camps, F. E., & Eccleston, E. G. (1967) · British Journal of Psychiatry · doi:10.1192/bjp.113.505.1407 · Cited by 431
Sánchez, C., & Hyttel, J. (1999) · Cellular and Molecular Neurobiology · doi:10.1023/a:1006986824213 · Cited by 429
Feyissa, A. M., Chandran, A., Stockmeier, C. A., & Karolewicz, B. (2009) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2008.10.005 · Cited by 421 · cited 6×
“…Karolewicz et al., 2009 NR2B Perirhinal cortex In situ hybridization Decreased Beneyto et al., 2007 Prefrontal cortex Western blot Decreased Feyissa et al., 2009 Locus coeruleus Polymerase chain reaction (PCR) Increased Chandley et al., 2014 NR2C Locus coeruleus Western blot Increased…”
BackgroundInfluentialThe Discovery of Fluoxetine Hydrochloride (Prozac)
Wong, D. T., Perry, K. W., & Bymaster, F. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1821 · Cited by 418
Beneyto, M., Kristiansen, L. V., Oni-Orisan, A., McCullumsmith, R. E., & Meador-Woodruff, J. H. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301312 · Cited by 408
A Double-Blind, Placebo-Controlled Study of Memantine in the Treatment of Major Depression
Zarate, C. A., Singh, J. B., Quiroz, J. A., De Jesus, G., Denicoff, K. K., Luckenbaugh, D. A., Manji, H. K., & Charney, D. S. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.153 · Cited by 387
Birnbaum, H. G., Kessler, R. C., Kelley, D., Ben-Hamadi, R., Joish, V. N., & Greenberg, P. E. (2010) · Depression and Anxiety · doi:10.1002/da.20580 · Cited by 380
Heninger, G., Delgado, P., & Charney, D. (1996) · Pharmacopsychiatry · doi:10.1055/s-2007-979535 · Cited by 380
Wong, D. T., Bymaster, F. P., Horng, J. S., & Molloy, B. B. (1975) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)30202-8 · Cited by 373
Bernard, R., Kerman, I. A., Thompson, R. C., Jones, E. G., Bunney, W. E., Barchas, J. D., Schatzberg, A. F., Myers, R. M., Akil, H., & Watson, S. J. (2011) · Molecular Psychiatry · doi:10.1038/mp.2010.44 · Cited by 372
Binding of antidepressants to human brain receptors: focus on newer generation compounds
Cusack, B., Nelson, A., & Richelson, E. (1994) · Psychopharmacology · doi:10.1007/bf02244985 · Cited by 349
Price, R. B., Iosifescu, D. V., Murrough, J. W., Chang, L. C., Al Jurdi, R. K., Iqbal, S. Z., Soleimani, L., Charney, D. S., Foulkes, A. L., & Mathew, S. J. (2014) · Depression and Anxiety · doi:10.1002/da.22253 · Cited by 345
Monoamine dysfunction and the pathophysiology and treatment of depression.
Charney, D. S. (1998) · PubMed · Cited by 342
An Open-Label Trial of Riluzole in Patients With Treatment-Resistant Major Depression
Zarate, C. A., Payne, J. L., Quiroz, J., Sporn, J., Denicoff, K. K., Luckenbaugh, D., Charney, D. S., & Manji, H. K. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.1.171 · Cited by 324
Subunit- and site-specific pharmacology of the NMDA receptor channel
Yamakura, T., & Shimoji, K. (1999) · Progress in Neurobiology · doi:10.1016/s0301-0082(99)00007-6 · Cited by 311
Ibrahim, L., DiazGranados, N., Franco-Chaves, J., Brutsche, N., Henter, I. D., Kronstein, P., Moaddel, R., Wainer, I., Luckenbaugh, D. A., Manji, H. K., et al. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.338 · Cited by 309
Papakostas, G. I., Thase, M. E., Fava, M., Nelson, J. C., & Shelton, R. C. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.03.027 · Cited by 308
Pfleiderer, B., Michael, N., Erfurth, A., Ohrmann, P., Hohmann, U., Wolgast, M., Fiebich, M., Arolt, V., & Heindel, W. (2003) · Psychiatry Research: Neuroimaging · doi:10.1016/s0925-4927(03)00003-9 · Cited by 301
Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats
Mørk, A., Montezinho, L. P., Miller, S., Trippodi-Murphy, C., Plath, N., Li, Y., Gulinello, M., & Sanchez, C. (2013) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2013.01.019 · Cited by 298
Mathew, S. J., Murrough, J. W., aan het Rot, M., Collins, K. A., Reich, D. L., & Charney, D. S. (2010) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709000169 · Cited by 294
Delgado, P. L. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950110025005 · Cited by 289
Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants
Browne, C. A., & Lucki, I. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00161 · Cited by 285
Burgdorf, J., Zhang, X.-L., Nicholson, K. L., Balster, R. L., David Leander, J., Stanton, P. K., Gross, A. L., Kroes, R. A., & Moskal, J. R. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2012.246 · Cited by 284
Do the dissociative side effects of ketamine mediate its antidepressant effects?
Luckenbaugh, D. A., Niciu, M. J., Ionescu, D. F., Nolan, N. M., Richards, E. M., Brutsche, N. E., Guevara, S., & Zarate, C. A. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.02.017 · Cited by 283
Mørk, A., Pehrson, A., Brennum, L. T., Nielsen, S. M., Zhong, H., Lassen, A. B., Miller, S., Westrich, L., Boyle, N. J., Sánchez, C., et al. (2012) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.189068 · Cited by 271
Lally, N., Nugent, A. C., Luckenbaugh, D. A., Ameli, R., Roiser, J. P., & Zarate, C. A. (2014) · Translational Psychiatry · doi:10.1038/tp.2014.105 · Cited by 271
Alzheimer disease: progress or profit?
Mount, C., & Downton, C. (2006) · Nature Medicine · doi:10.1038/nm0706-780 · Cited by 262
MICHAEL, N., ERFURTH, A., OHRMANN, P., AROLT, V., HEINDEL, W., & PFLEIDERER, B. (2003) · Psychological Medicine · doi:10.1017/s0033291703007931 · Cited by 260
Beneyto, M., & Meador-Woodruff, J. H. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301604 · Cited by 259
15 Years of Clinical Experience With Bupropion HCl: From Bupropion to Bupropion SR to Bupropion XL
Fava, M., Rush, A. J., Thase, M. E., Clayton, A., Stahl, S. M., Pradko, J. F., & Johnston, J. A. (2005) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v07n0305 · Cited by 258
Duncan, W. C., Sarasso, S., Ferrarelli, F., Selter, J., Riedner, B. A., Hejazi, N. S., Yuan, P., Brutsche, N., Manji, H. K., Tononi, G., et al. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000545 · Cited by 256
Zarate, C. A., Mathews, D., Ibrahim, L., Chaves, J. F., Marquardt, C., Ukoh, I., Jolkovsky, L., Brutsche, N. E., Smith, M. A., & Luckenbaugh, D. A. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.10.019 · Cited by 255
Haile, C. N., Murrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Foulkes, A., Iqbal, S., Mahoney, J. J., De La Garza, R., Charney, D. S., et al. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713001119 · Cited by 253
Thomas, D. R., Nelson, D. R., & Johnson, A. M. (1987) · Psychopharmacology · doi:10.1007/bf00179933 · Cited by 251
Plasma and platelet excitatory amino acids in psychiatric disorders
(1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.11.1731 · Cited by 243
Increased cerebrospinal fluid glutamine levels in depressed patients
Levine, J., Panchalingam, K., Rapoport, A., Gershon, S., McClure, R. J., & Pettegrew, J. W. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00284-x · Cited by 240 · cited 8×
“, 1998) and increased concentration of glutamine in cerebrospinal fluid (Levine et al., 2000).”
BackgroundInfluentialProperties of the interaction between ketamine and opiate binding sites in vivo and in vitro
SMITH, D., BOUCHAL, R., DESANCTIS, C., MONROE, P., AMEDRO, J., PERROTTI, J., & CRISP, T. (1987) · Neuropharmacology · doi:10.1016/0028-3908(87)90084-0 · Cited by 237
Sanacora, G., Smith, M. A., Pathak, S., Su, H.-L., Boeijinga, P. H., McCarthy, D. J., & Quirk, M. C. (2014) · Molecular Psychiatry · doi:10.1038/mp.2013.130 · Cited by 236
Compositional Lineation and Its Relation to Complex Folding
Newhouse, W. H. (1955) · Science · doi:10.1126/science.122.3163.284-a · Cited by 232
Mauri, M. C., Ferrara, A., Boscati, L., Bravin, S., Zamberlan, F., Alecci, M., & Invernizzi, G. (1998) · Neuropsychobiology · doi:10.1159/000026491 · Cited by 231
Current Place of Monoamine Oxidase Inhibitors in the Treatment of Depression
Shulman, K. I., Herrmann, N., & Walker, S. E. (2013) · CNS Drugs · doi:10.1007/s40263-013-0097-3 · Cited by 227
Compositional Lineation and Its Relation to Complex Folding
Newhouse, W. H. (1955) · Science · doi:10.1126/science.122.3163.284.a · Cited by 226
Ibrahim, L., DiazGranados, N., Jolkovsky, L., Brutsche, N., Luckenbaugh, D. A., Herring, W. J., Potter, W. Z., & Zarate, C. A. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31825d70d6 · Cited by 220
Mathews, D. C., Henter, I. D., & Zarate, C. A. (2012) · Drugs · doi:10.2165/11633130-000000000-00000 · Cited by 220
Serial infusions of low-dose ketamine for major depression
Rasmussen, K. G., Lineberry, T. W., Galardy, C. W., Kung, S., Lapid, M. I., Palmer, B. A., Ritter, M. J., Schak, K. M., Sola, C. L., Hanson, A. J., et al. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113478283 · Cited by 217
The prevalence and natural history of urinary symptoms among recreational ketamine users
Winstock, A. R., Mitcheson, L., Gillatt, D. A., & Cottrell, A. M. (2012) · BJU International · doi:10.1111/j.1464-410x.2012.11028.x · Cited by 214
Laje, G., Lally, N., Mathews, D., Brutsche, N., Chemerinski, A., Akula, N., Kelmendi, B., Simen, A., McMahon, F. J., Sanacora, G., et al. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.05.031 · Cited by 213
Wang, S.-J., Wang, K.-Y., & Wang, W.-C. (2004) · Neuroscience · doi:10.1016/j.neuroscience.2004.01.019 · Cited by 210
A clinical and pharmacodynamic evaluation of iproniazid as a psychic energizer.
Loomer, H. P., SAUNDERS, J. C., & Kline, N. S. (1957) · PubMed · Cited by 205
Valentine, G. W., Mason, G. F., Gomez, R., Fasula, M., Watzl, J., Pittman, B., Krystal, J. H., & Sanacora, G. (2011) · Psychiatry Research: Neuroimaging · doi:10.1016/j.pscychresns.2010.10.009 · Cited by 204
Dopamine receptor contribution to the action of PCP, LSD and ketamine psychotomimetics
Seeman, P., Ko, F., & Tallerico, T. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001682 · Cited by 200
Sanacora, G., Kendell, S. F., Levin, Y., Simen, A. A., Fenton, L. R., Coric, V., & Krystal, J. H. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.08.037 · Cited by 199
Different sensitivities of NMDA receptor channel subtypes to non-competitive antagonists
Yamakura, T., Mori, H., Masaki, H., Shimoji, K., & Mishina, M. (1993) · NeuroReport · doi:10.1097/00001756-199306000-00021 · Cited by 181
Maes, M., Verkerk, R., Vandoolaeghe, E., Lin, A., & Scharpé, S. (1998) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1998.tb10004.x · Cited by 179
Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity
Vaishnavi, S. N., Nemeroff, C. B., Plott, S. J., Rao, S. G., Kranzler, J., & Owens, M. J. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2003.07.006 · Cited by 178
A randomized add-on trial of high-dose d-cycloserine for treatment-resistant depression
Heresco-Levy, U., Gelfin, G., Bloch, B., Levin, R., Edelman, S., Javitt, D. C., & Kremer, I. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000910 · Cited by 177
Boulenger, J.-P., Loft, H., & Olsen, C. K. (2014) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000018 · Cited by 176
Riluzole increases high-affinity glutamate uptake in rat spinal cord synaptosomes
Azbill, R. D., Mu, X., & Springer, J. E. (2000) · Brain Research · doi:10.1016/s0006-8993(00)02430-6 · Cited by 175
ROLE OF BRAIN SEROTONIN IN RESERPINE ACTION
Shore, P. A., Pletscher, A., Tomich, E. G., Carlsson, A., Kuntzman, R., & Brodie, B. B. (1957) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1957.tb40751.x · Cited by 173
Machado-Vieira, R., Manji, H. K., & Zarate, C. A. (2009) · The Neuroscientist · doi:10.1177/1073858409336093 · Cited by 171
Depression research: where are we now?
Lee, S., Jeong, J., Kwak, Y., & Park, S. K. (2010) · Molecular Brain · doi:10.1186/1756-6606-3-8 · Cited by 170
Irwin, S. A., Iglewicz, A., Nelesen, R. A., Lo, J. Y., Carr, C. H., Romero, S. D., & Lloyd, L. S. (2013) · Journal of Palliative Medicine · doi:10.1089/jpm.2012.0617 · Cited by 167
Clinical Predictors of Ketamine Response in Treatment-Resistant Major Depression
Niciu, M. J., Luckenbaugh, D. A., Ionescu, D. F., Guevara, S., Machado-Vieira, R., Richards, E. M., Brutsche, N. E., Nolan, N. M., & Zarate, C. A. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08698 · Cited by 165
Roth, B. L., Gibbons, S., Arunotayanun, W., Huang, X., Setola, V., Treble, R., & Iversen, L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059334 · Cited by 163
Block, W., Träber, F., von Widdern, O., Metten, M., Schild, H. H., Maier, W., Zobel, A. W., & Jessen, F. (2008) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145708009516 · Cited by 162
Lotufo-Neto, F. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00075-x · Cited by 159
Management of Patients With Treatment-Resistant Depression
Thase, M. E. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.0308e08 · Cited by 158
Ghasemi, M., Kazemi, M., Yoosefi, A., Ghasemi, A., Paragomi, P., Amini, H., & Afzali, M. H. (2013) · Psychiatry Research · doi:10.1016/j.psychres.2013.12.008 · Cited by 156
Machado-Vieira, R., Yuan, P., Brutsche, N., DiazGranados, N., Luckenbaugh, D., Manji, H. K., & Zarate, C. A. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04659 · Cited by 155
Küçükibrahimoğlu, E., Saygın, M. Z., Çalışkan, M., Kaplan, O. K., Ünsal, C., & Gören, M. Z. (2009) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-009-0650-7 · Cited by 155
Pristupa, Z. B., Wilson, J. M., Hoffman, B. J., Kish, S. J., & Niznik, H. B. (1994) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09894-3 · Cited by 153
Nudmamud‐Thanoi, S., & Reynolds, G. P. (2004) · Neuroscience Letters · doi:10.1016/j.neulet.2004.09.035 · Cited by 150
Millan, M. J., Gobert, A., Lejeune, F., Newman‐Tancredi, A., Rivet, J., Auclair, A., & Péglion, J.-L. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29415-5 · Cited by 149
Elevated levels of NR2A and PSD-95 in the lateral amygdala in depression
Karolewicz, B., Szebeni, K., Gilmore, T., Maciąg, D., Stockmeier, C. A., & Ordway, G. A. (2008) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145708008985 · Cited by 148
Chandley, M., Szebeni, A., Szebeni, K., Crawford, J. D., Stockmeier, C. A., Turecki, G., Kostrzewa, R. M., & Ordway, G. A. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145714000662 · Cited by 145
Lara, D. R., Bisol, L. W., & Munari, L. R. (2013) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713000485 · Cited by 142
Uher, R., Mors, O., Rietschel, M., Rajewska-Rager, A., Petrovic, A., Zobel, A., Henigsberg, N., Mendlewicz, J., Aitchison, K., Farmer, A., et al. (2011) · Journal of Clinical Psychiatry · doi:10.4088/jcp.10m06419 · Cited by 139
DEPRESSION AND ANXIETY OCCURRING DURING RAUWOLFIA THERAPY
Muller, J. C. (1955) · JAMA · doi:10.1001/jama.1955.02960260006002 · Cited by 134
du Jardin, K. G., Jensen, J. B., Sanchez, C., & Pehrson, A. L. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.07.001 · Cited by 133
Moskal, J. R., Burch, R. M., Burgdorf, J. S., Kroes, R. A., Stanton, P. K., Disterhoft, J. F., & Leander, J. D. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.852536 · Cited by 133
Reduced Anterior Cingulate Cortex Glutamatergic Concentrations in Childhood Major Depression
Mirza, Y., Tang, J., Russell, A., Banerjee, S. P., Bhandari, R. P., Ivey, J., Rose, M., Moore, G. J., & Rosenberg, D. R. (2004) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200403000-00017 · Cited by 130
Ketamine inhibits monoamine transporters expressed in human embryonic kidney 293 cells
Nishimura, M., Sato, K., Okada, T., Yoshiya, I., Schloss, P., Shimada, S., & Tohyama, M. (1998) · Anesthesiology · doi:10.1097/00000542-199803000-00029 · Cited by 128
Boulenger, J.-P., Loft, H., & Florea, I. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112441866 · Cited by 127
Shiroma, P. R., Albott, C. S., Johns, B., Thuras, P., Wels, J., & Lim, K. O. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145714001011 · Cited by 126
Monoamine Oxidase (MAO) in Human Peripheral Tissues
Billett, E. E. (2003) · NeuroToxicology · doi:10.1016/s0161-813x(03)00094-9 · Cited by 123
Oral Ketamine for the Rapid Treatment of Depression and Anxiety in Patients Receiving Hospice Care
Irwin, S. A., & Iglewicz, A. (2010) · Journal of Palliative Medicine · doi:10.1089/jpm.2010.9808 · Cited by 123
Muhonen, L. H., Lönnqvist, J. K., Juva, K., & Alho, H. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0308 · Cited by 118
Bresink, I., Danysz, W., Parsons, C. G., & Mutschler, E. (1995) · Neuropharmacology · doi:10.1016/0028-3908(95)00017-z · Cited by 117
5-Year Trends in Use of Hallucinogens and Other Adjunct Drugs among UK Dance Drug Users
McCambridge, J., WINSTOCK, A. R., Hunt, N., & Mitcheson, L. (2006) · European Addiction Research · doi:10.1159/000095816 · Cited by 116
Murrough, J. W., Wan, L.-B., Iacoviello, B. M., Collins, K. A., SOLON, C. A., Glicksberg, B. S., Perez, A. M., Mathew, S. J., Charney, D. S., Iosifescu, D. V., et al. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3255-x · Cited by 114
Guillain-Barre syndrome following zimeldine treatment.
Fagius, J., OSTERMAN, P. O., Sidén, Å., & Wiholm, B. ‐. (1985) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.48.1.65 · Cited by 107
The discovery of antidepressants: A winding path
Pletscher, A. (1991) · Cellular and Molecular Life Sciences · doi:10.1007/bf02041242 · Cited by 99
Half a Century of Antidepressant Drugs
Lopez-Munoz, F. J., Álamo, C., Juckel, G., & Assion, H. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181bb617 · Cited by 99
Jensen, J. B., du Jardin, K. G., Song, D., Budac, D., Smagin, G., Sanchez, C., & Pehrson, A. L. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.10.011 · Cited by 96 · cited 1×
“It is important to note that clinical (McIntyre, Lophaven, & Olsen, 2014) and preclinical (du Jardin, Jensen, Sanchez, & Pehrson, 2014; Jensen et al., 2014; Mork et al., 2013) studies have shown that vortioxetine may help improve cognitive functioning.”
BackgroundMoskal, J. R., Kuo, A. G., Weiss, C., Wood, P. L., Hanson, A. O., Kelso, S. R., Harris, R. B., & Disterhoft, J. F. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.06.006 · Cited by 91
Controlled trial of d-cycloserine adjuvant therapy for treatment-resistant major depressive disorder
Heresco-Levy, U., Javitt, D. C., Gelfin, Y., Gorelik, E., Bar, M., Blanaru, M., & Kremer, I. (2006) · Journal of Affective Disorders · doi:10.1016/j.jad.2006.03.004 · Cited by 89
Acute Antidepressant Effects of Intramuscular Versus Intravenous Ketamine
Chilukuri, H., Reddy, N. P., Pathapati, R. M., Manu, A. N., Jollu, S., & Shaik, A. B. (2014) · Indian Journal of Psychological Medicine · doi:10.4103/0253-7176.127258 · Cited by 89
Sigma opioid receptor: characterization and co-identity with the phencyclidine receptor.
Mendelsohn, L. G., Kalra, D., Johnson, B. G., et al. (1985) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22867-1 · Cited by 89
Moaddel, R., Luckenbaugh, D. A., Xie, Y., Villaseñor, A., Brutsche, N. E., Machado-Vieira, R., Ramamoorthy, A., Lorenzo, M. P., Garcia, A., Bernier, M., et al. (2015) · Psychopharmacology · doi:10.1007/s00213-014-3669-0 · Cited by 86
The Involvement of Glutamate in the Pathophysiology of Depression
Pałucha-Poniewiera, A., & Pilc, A. (2005) · Drug News & Perspectives · doi:10.1358/dnp.2005.18.4.908661 · Cited by 84
Smith, E. G., Deligiannidis, K. M., Ulbricht, C. M., Landolin, C. S., Patel, J. K., & Rothschild, A. J. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12m08252 · Cited by 82
Lack of behavioral effects of monoamine depletion in healthy subjects.
Salomon, R., Miller, H. L., Krystal, J., Heninger, G., & Charney, D. (1997) · Biological Psychiatry · doi:10.1016/0006-3223(95)00670-2 · Cited by 80
Alam, M. Y., Jacobsen, P. L., Chen, Y., Serenko, M., & Mahableshwarkar, A. R. (2013) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000010 · Cited by 77
Half a Century of Antidepressant Drugs
Fangmann, P., Assion, H., Juckel, G., González, C. Á., & Lopez-Munoz, F. J. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181627b60 · Cited by 76
Elevated Levels of the NR2C Subunit of the NMDA Receptor in the Locus Coeruleus in Depression
Karolewicz, B., Stockmeier, C. A., & Ordway, G. A. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300781 · Cited by 76
Tackling Adolescent Substance Abuse in Hong Kong: Where We Should and Should Not Go
Shek, D. T. L. (2007) · The Scientific World JOURNAL · doi:10.1100/tsw.2007.315 · Cited by 68
Vortioxetine: First Global Approval
Gibb, A. D., & Deeks, E. D. (2013) · Drugs · doi:10.1007/s40265-013-0161-9 · Cited by 66
Marsden, W. N. (2011) · Medical Hypotheses · doi:10.1016/j.mehy.2011.06.021 · Cited by 66
Lenze, E. J., Skidmore, E. R., Begley, A. E., Newcomer, J. W., Butters, M. A., & Whyte, E. M. (2012) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2813 · Cited by 63
Platelet Glutamate Receptor Supersensitivity in Major Depressive Disorder
Berk, M., Plein, H., & Ferreira, D. (2001) · Clinical Neuropharmacology · doi:10.1097/00002826-200105000-00002 · Cited by 63
Double-Blind Comparison of Doxepin Versus Bupropion in Outpatients with a Major Depressive Disorder
Feighner, J. P., HENDRICKSON, G. G., Miller, L. L., & Stern, W. C. (1986) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198602000-00006 · Cited by 61
History of Modern Psychopharmacology: A Personal View With an Emphasis on Antidepressants
Domino, E. F. (1999) · Psychosomatic Medicine · doi:10.1097/00006842-199909000-00002 · Cited by 61
Monoamine depletion in unmedicated depressed subjects.
Berman, R., Sanacora, G., Anand, A., Roach, L. M., Fasula, M. K., Finkelstein, C., Wachen, R., Oren, D., Heninger, G., & Charney, D. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01285-9 · Cited by 53
The Efficacy and Tolerability of Bupropion in the Treatment of Major Depressive Disorder
Moreira, R. (2011) · Clinical Drug Investigation · doi:10.2165/1159616-s0-000000000-00000 · Cited by 50
A double-blind study of bupropion and placebo in depression
Feighner, J. P., Meredith, C. H., Stern, W. C., HENDRICKSON, G. G., & Miller, L. L. (1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.4.525 · Cited by 45
Hirota, K., Hashimoto, Y., & Lambert, D. G. (2002) · Anesthesia & Analgesia · doi:10.1097/00000539-200212000-00025 · Cited by 38
Lord, B., Wintmolders, C., Langlois, X., Nguyen, L., Lovenberg, T., & Bonaventure, P. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.06.028 · Cited by 37
Garakani, A., Martinez, J. M., Yehuda, R., & Gorman, J. M. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.06.037 · Cited by 32
McNulty, J. P., & Hahn, K. (2012) · PubMed · Cited by 29
Zigman, D., & Blier, P. (2013) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3182856865 · Cited by 27
Vortioxetine for the Treatment of Depression
Pearce, E. F., & Murphy, J. A. (2014) · Annals of Pharmacotherapy · doi:10.1177/1060028014528305 · Cited by 27
Jordan, S., Chen, R., Fernalld, R., Johnson, J. L., Regardie, K., Kambayashi, J., Tadori, Y., Kitagawa, H., & Kikuchi, T. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.04.026 · Cited by 26
Riluzole likely lacks antidepressant efficacy in ketamine non-responders
Niciu, M. J., Luckenbaugh, D. A., Ionescu, D. F., Richards, E. M., Voort, J. L. V., Ballard, E. D., Brutsché, N. E., Furey, M. L., & Zarate, C. A. (2014) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2014.07.022 · Cited by 22
Chen, T., & Tzeng, N. (2013) · Medical Hypotheses · doi:10.1016/j.mehy.2013.05.009 · Cited by 14
Cited by
Major depressive disorder: hypothesis, mechanism, prevention and treatment
Cui, L., Li, S., Wang, S., Wu, X., Liu, Y., Yu, W., Wang, Y., Tang, Y., Xia, M., & Li, B. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01738-y · Cited by 1,244
“342 TCAs have a common three-ring chemical structure, and the main TCAs are imipramine, amitriptyline, clomipramine, desipramine and doxepin.”
BackgroundZhang, J.-C., Yao, W., & Hashimoto, K. (2016) · Current Neuropharmacology · doi:10.2174/1570159x14666160119094646 · Cited by 538
Light Affects Mood and Learning through Distinct Retina-Brain Pathways
Fernandez, D. C., Fogerson, P. M., Lazzerini Ospri, L., Thomsen, M. B., Layne, R. M., Severin, D., Zhan, J., Singer, J. H., Kirkwood, A., Zhao, H., et al. (2018) · Cell · doi:10.1016/j.cell.2018.08.004 · Cited by 505
Addressing the Side Effects of Contemporary Antidepressant Drugs: A Comprehensive Review
Wang, S.-M., Han, C., Bahk, W.-M., Lee, S.-J., Patkar, A. A., Masand, P. S., & Pae, C.-U. (2018) · Chonnam Medical Journal · doi:10.4068/cmj.2018.54.2.101 · Cited by 299
The future of rodent models in depression research
Gururajan, A., Reif, A., Cryan, J. F., & Slattery, D. A. (2019) · Nature Reviews Neuroscience · doi:10.1038/s41583-019-0221-6 · Cited by 269
Metadata
- Authors
- Hillhouse, T. M., & Porter, J. H.
- Venue
- Experimental and Clinical Psychopharmacology
- Published
- 2015-02
- Volume
- 23
- Issue
- 1
- Pages
- 1-21
- ISSN
- 1064-1297 (ISSN-L)
- 1936-2293
- OpenAlex
- W2048175288
- Cited by
- 605
- References
- 171
- FWCI
- 12.06
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.